Answers are grounded in this paper and cite their sources.
OBJECTIVE: To assess the effect of dalfampridine tablets in clinical practice in patients with neuromyelitis optica ( NMO) with walking impairment BACKGROUND: Dalfampridine improve walking disability in NMO. DESIGN/METHODS: Fifteen NMO patients with EDSS scores between 4 to 7 were included. Clinical assemements : Time-25-foot Walk (T25FW), multiple sclerosis Walking Scale (MSWS-12), french validated self questionnaires on fatigue ( EMIF-SEP) and quality of life in multiple sclerosis( SEP-59) were performed at baseline and after two weeks with treatment with fampridine tablets 10 mg twice daily. Differences data across groups were assessed by the two-tailed Student's t-test. RESULTS:Side effect and early treatment disruption were observed in 1 case without control clinical assements. In the cohort of 14 patients T25FW was statistically reduced with dalfampridine treatment (p<0,05) with change on the T25FW>20[percnt] in 66,6[percnt] of ameliorated patients. MSWS-12 scores was also improved with treatment (p<0,05). Self questionnaire SEP-59 and EMIF-SEP at two weeks improved in all subscales after treatment but the difference reached signifance for the psychological dimension and social fonction subscale of SEP-59 only. CONCLUSIONS: As in multiple sclerosis, dalfampridine could be useful for symptomatic treatment of walking impairment in NMO. Other studies with large cohort of patients are necessary to confirm these preliminary results as well as the impact of dalfampridine on fatigue and quality of life in NMO.
No takes yet. Share an insight, caveat, or question.
Christine et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: